{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:03:28Z","timestamp":1783609408604,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajt.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:26:24Z","timestamp":1755012384000},"page":"2611-2620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3757-4986","authenticated-orcid":false,"given":"Eunice","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4595-2512","authenticated-orcid":false,"given":"Nilah","family":"Ahimsadasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-0603","authenticated-orcid":false,"given":"Naomi Khaing","family":"Than Hlaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1357-5916","authenticated-orcid":false,"given":"Janessa","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-5157","authenticated-orcid":false,"given":"Sara","family":"Naimimohasses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7579-2140","authenticated-orcid":false,"given":"Shiyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-8449","authenticated-orcid":false,"given":"Mamatha","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajt.2025.08.003_bib1","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.ajt.2025.08.003_bib2","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/HEP.0000000000000606","article-title":"RNA nanomedicine in liver diseases","volume":"81","author":"Bakrania","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ajt.2025.08.003_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"38","key":"10.1016\/j.ajt.2025.08.003_bib4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ajt.2025.08.003_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"10.1016\/j.ajt.2025.08.003_bib6","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ejhf.1756","article-title":"Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome","volume":"22","author":"Nitsche","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.ajt.2025.08.003_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"29","key":"10.1016\/j.ajt.2025.08.003_bib8","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.1016\/j.ajt.2025.08.003_bib9","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/ckj\/sfab203","article-title":"Primary hyperoxaluria type 1 in developing countries: novel challenges in a new therapeutic era","volume":"15","author":"Soliman","year":"2022","journal-title":"Clin Kidney J"},{"issue":"9","key":"10.1016\/j.ajt.2025.08.003_bib10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbadis.2012.03.004","article-title":"Primary hyperoxalurias: disorders of glyoxylate detoxification","volume":"1822","author":"Salido","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.ajt.2025.08.003_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/MOT.0b013e32833e35f5","article-title":"Primary hyperoxaluria type 1: strategy for organ transplantation","volume":"15","author":"Cochat","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2025.08.003_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0000000000001021","article-title":"Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP world transplant registry","volume":"100","author":"Suhr","year":"2016","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.ajt.2025.08.003_bib13","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2025.08.003_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12876-020-01349-1","article-title":"Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the Scientific Registry of Transplant Recipients Database","volume":"20","author":"Xiang","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.ajt.2025.08.003_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.ajt.2025.08.003_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000508262","article-title":"Solid organ transplantation in amyloidosis","volume":"143","author":"Theodorakakou","year":"2020","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.ajt.2025.08.003_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ajt.2025.08.003_bib18","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/jama.2023.4570","article-title":"SiRNAs-A new class of medicines","volume":"329","author":"Khvorova","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajt.2025.08.003_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ajt.2025.08.003_bib20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajt.2025.08.003_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.ajt.2025.08.003_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cardfail.2023.10.302","article-title":"The use of patisiran for the improvement of cardiac parameters in hereditary transthyretin-mediated amyloidosis: a systematic review and meta-analysis","volume":"30","author":"Charles","year":"2024","journal-title":"J Card Fail"},{"issue":"13","key":"10.1016\/j.ajt.2025.08.003_bib23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajt.2025.08.003_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/brainsci11040515","article-title":"Patisiran in hATTR amyloidosis: six-month latency period before efficacy","volume":"11","author":"Gentile","year":"2021","journal-title":"Brain Sci"},{"issue":"5","key":"10.1016\/j.ajt.2025.08.003_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae099","article-title":"Primary hyperoxaluria in adults and children: a nationwide cohort highlights a persistent diagnostic delay","volume":"17","author":"Pszczolinski","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.ajt.2025.08.003_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jhep.2013.04.004","article-title":"Monogenic diseases that can be cured by liver transplantation","volume":"59","author":"Fagiuoli","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ajt.2025.08.003_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525028849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525028849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:35:17Z","timestamp":1778621717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613525028849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1600613525028849"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2025.08.003","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}